Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Neuroone Medical Technologies (NMTC) Capital Expenditures (2021 - 2025)

Neuroone Medical Technologies' Capital Expenditures history spans 5 years, with the latest figure at $40754.0 for Q4 2025.

  • For Q4 2025, Capital Expenditures rose 66.92% year-over-year to $40754.0; the TTM value through Dec 2025 reached $112682.0, up 4.84%, while the annual FY2025 figure was $81742.0, 31.99% down from the prior year.
  • Capital Expenditures reached $40754.0 in Q4 2025 per NMTC's latest filing, up from $10607.0 in the prior quarter.
  • In the past five years, Capital Expenditures ranged from a high of $175694.0 in Q1 2023 to a low of $10607.0 in Q3 2025.
  • Average Capital Expenditures over 5 years is $54137.5, with a median of $37131.0 recorded in 2023.
  • Peak YoY movement for Capital Expenditures: skyrocketed 222.54% in 2023, then plummeted 89.37% in 2024.
  • A 5-year view of Capital Expenditures shows it stood at $61491.0 in 2021, then crashed by 81.28% to $11512.0 in 2022, then surged by 222.54% to $37131.0 in 2023, then tumbled by 34.24% to $24416.0 in 2024, then surged by 66.92% to $40754.0 in 2025.
  • Per Business Quant, the three most recent readings for NMTC's Capital Expenditures are $40754.0 (Q4 2025), $10607.0 (Q3 2025), and $24416.0 (Q4 2024).